Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I would suggest you go to the regent pacific group website and look at the announcements regarding the DBC and how much RPG paid for their investment. Look at announcements at the beginning of the year. It will provide you with some insight. From what I remember the 2nd of a 3 x mill squid investment in shares was to be on the 15th Oct, which as far as RPG share holders are concerned was not made. These were meant to be at around the 23gbp/ share Mark. I hope it helps.
Daisan, just been looking at this. Company had just over $1m in liquid or near liquid form at 29 September, current value c. £800K. If say £750K is left for the 7% investment in DBC, that will value DBC at c. £10.7m. DBC has 605,477 shares currently in issue, which would value the shares at c. £17.70 each. Looking back to July 2015, the shares were changing hands at about £13.40 each; so £17.70 does not seem out of line, considering that we are 16 months further on. This article at http://www.gecr.co.uk/latest-research/2015/7/27/the-diabetic-boot-company-targeting-a-significant-global-unmet-need considered the possibility of the shares being worth £30.61 assuming a high discount rate of 40% and a market share of just 5% and assuming a lower discount rate of 30%, a target price of £63.59, or 3.6 times the £17.70 issue price that I have supposed from my rough calculations. Of course this is all speculation, but it is encouraging to consider when the RTO eventually happens. I have no idea how much longer we have to wait for the details of the RTO to be issued; at worst we might have to wait until March next year when the 6 month AIM time limit ends. DBC seems to be attending one exhibition /conference after another all part of the marketing needed. Patience will be rewarded I trust!
Any ideas of when we will hear something? What's the deadline date for news?
Dear Jim, Could you please update us with any progress on the RTO of the Diabetic Boot Company. I am patiently waiting. Yours sincerely Shareholder
If this goes to plan then I am expecting big things. I have done my research and the market for this product is huge!
This report does date from July 2015, and we do not know at what value the company will come to market, but do like the following extracts from the investment report: Assuming a high discount rate of 40% and a market share of just 5%, we estimate the shares could be worth £30.61, which suggests upside of 129% from the current price. Competition: While there are numerous clinical trials ongoing in the US for treating DFUs, we did not identify any trials for products similar to Pulseflow DF. Furthermore, to date, no other marketed devices have been identified which combine offloading and intermittent plantar compression. Valuation: Also, assuming a lower discount rate of 30%, this would translate to a target price of £63.59, or upside of 376%. The company expects to exit in 3-5 years via a trade sale or IPO. The company's shares are currently privately traded.
Also this which shows the massive potential for Pulseflow https://static1.squarespace.com/static/5371fb22e4b0a7ee8e9a6c3e/t/55cdd82ce4b0a4f80be7a204/1439553580286/DBC+Investment+report.pdf
Hi Reg - interesting - it does seem there is massive potential with DBC both here, in the US and indeed worldwide, the US in particular, as needless to say due to the size of its market and the higher degree of private medicine. Found this article amongst others dating from July 2015, which you may have seen yourself: http://www.gecr.co.uk/latest-research/2015/7/27/the-diabetic-boot-company-targeting-a-significant-global-unmet-need . Getting more excited about this now having purchased shares in the week before they were suspended on the back of Jim Mellon's involvement. We could be in for a bagger on this RTO.
There was also an interesting article on inside out south last night on the BBC all about diabetes and the nhs. Over 10% of the entire nhs budget is spent on diabetes care which is 18 billion pounds. Most of that is spent on care after amputation of feet and toes, the nhs are desperate for ways to prevent amputation due to the costs, these boots appear to be an interesting option. Diabetes is a massive growing issue
Have been looking at what the Diabetic Boot Company have been doing since it was announced that LIFE intends to arrange an RTO with them. From their website for they say the following:- Autumn is traditionally 'busy season' for congresses and exhibitions. As healthcare professionals and business folk return to their desks and clinics after the summer, calendars are often full of symposia and conferences at which to share ideas, information and the latest research. PulseFlow Technologies is no different and our calendar for the autumn is looking pretty hectic! Next week we'll be attending the Nordic Diabetic Foot congress in Copenhagen, Denmark, and exhibiting at the Symposium on Advanced Wound Care (SAWC) Fall meeting in Las Vegas, USA - a multidisciplinary forum for all members of the wound care team and the first outing for our new booth! Our European team will then turn their focus to the Pisa International Diabetic Foot Course, which combines lectures and in-clinic training, while our US team set up for Desert Foot in Phoenix, Arizona, focussing on both diabetes-related and non-diabetes-related lower limb pathologies. Then, in November, it's on to Medica in Dusseldorf, Germany - the world's leading trade fair for the medical industry - and Diabetes Professional Care in London, UK. The Pisa International DF Course was held between 12 and 15 October and the company are currently at the Desert Foot Conference which is on between 19 and 22 October. So the publicity goes on and DBC were a sponsor of the Pisa event. Back in February 2016, Les Lindsay the CEO of DBC advised Master Investor that they gained the green light, FDA 510k clearance, in December 2015, which was a huge milestone for them. The next biggest challenge was to get final sign-off on a US reimbursement rate at a high enough level. He guessed that they were now 85% through that process, so a very significant short-term milestone was to have that rate approved by CMS/Medicare before May 2016. That meant that they had clearance to market and a reimbursement rate to go forth and multiply in the DFU plague present in the USA. After the USA, with existing regulatory affairs clearances (CE mark etc.) he looked for significant revenues coming from Distribution partners already signed up. All of the above was dependent upon ramping up production capacity in the short term, and they were probably 90% complete on that, awaiting formal contracts being signed up. They were to commission large scale cost effectiveness / health economics studies in 2016, and anticipated reporting by 2017. My thought is that that might link in with the RTO perhaps being before the year end. It looks quite an exciting prospect and I am hopeful that shareholders, of which I and my wife are, will see a material increase in our investment.
Cheers for finding that nice to see it in the real world working, not always easy to picture it in an rns.
Regent pacific group. Another JM investment vehicle also has a slice of the pie. This link may be of interest. http://lifesciencedevelopments.com/news/06.10.16_LIFE-Announcement-RNS-DBC-Acquisition.pdf
Jim Mellon, the biotech investor, is putting his best foot forward with his latest stock market foray. The Diabetic Boot Company, as the medical shoe-maker is known, is currently exploring all forms of financing after an initial £1m investment round, with the preferred outcome a flotation on Aim, pencilled in for late August. No banks have been appointed as advisers yet, but Mellon, who owns a 40pc stake in the company through his Burnbrae vehicle, estimates its IPO valuation at around £15m. ------------------------------------------------------------------
What are views on this? According to Company Check the company has a net worth of £1.1m as of February. With shareholders here having 7% (it says minimum but...) at current market capitalisation that would value the new entity at £12.5m.
before fund raising…………..seems a cheap way for Mellon to list and raise funds…….not sure what that leaves share holders here
Well good luck to all the folks that holding going into suspension interisting times ahead GLA
RNS was promised before suspension tomorrow morning. Directors are leaving it to the last possible moment it seems. Let's hope it says that they are nearing a proposed investment rather than a bland statement to say still looking at various possibilities. It would encourage shareholders!
And while it's suspended there will still be some cash burn through the reserves I take it.
I understand that the company has 6 months from suspension to arrange an RTO/investment before the AIM listing is cancelled. I am not aware of any other deadline, but I stand to be corrected.
I know the suspension happens on the 6th. How long do they then have to declare what their intentions are? It's normally 28 days, isn't it? but they can apply for an extension, right?
Many are exercising caution - not everyone wants their investment suspended. This remains a gamble, albeit a calculated one.
Can't believe the deafly hush! Nobody taking positions ahead of the news pre suspension on Thursday morning? I suppose everyone has decided to wait and see.
Now's the time to buy ahead of the 6th - deadline day. MCAP currently c. £940K, whilst the company has £800K in cash so only a small amount for the benefit of being an AIM share.The BoD very recently advised their intention to make an investment and to hopefully advise shareholders before the 6th. As they say the early bird.
Nobody here all chasing dreams of oil not reverse takeovers no twisting my mellon man ;)